Neurocrine Biosciences Licenses Seven Psychiatric Programmes from Takeda in US$2 B Deal
By Neha Madhwani & Michelle Liu
Pharma Deals Review: Vol 2020 Issue 7 (Table of Contents)
Published: 4 Jul-2020
DOI: 10.3833/pdr.v2020.i7.2548 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a bid to expand its neuroscience portfolio beyond its flagship product Ingrezza® (valbenazine), Neurocrine Biosciences has agreed to develop and commercialise seven of Takeda Pharmaceutical’s pipeline programmes: TAK-831 for schizophrenia, TAK-653 for treatment-resistant depression, TAK-041 for anhedonia, as well as four undisclosed preclinical assets in rare neurological diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS